Compare ProShares Ultra Gold ETF (UGL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Gold ETF vs Zoetis Inc — how do they compare? ProShares Ultra Gold ETF trades at $51.62, while Zoetis Inc trades at $73.9 (market cap $30.39B). The key difference: Zoetis Inc pays a 2.88% dividend while ProShares Ultra Gold ETF pays none, and ProShares Ultra Gold ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| UGL | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $85.62 | $156.76 |
52-Week Low | $34.37 | $71.91 |
Market Cap | — | $30.39B |
Enterprise Value | — | $37.95B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UGL is trading at $52.35, up 1.24% with a bullish technical signal from moving averages. The stock shows strong momentum indicators but overbought RSI readings suggest potential near-term consolidation. Recent gold market strength driven by inflation data and geopolitical tensions provides positive sector tailwinds.
The outlook remains positive given gold's safe-haven appeal amid economic uncertainty, though overbought technical conditions warrant caution. Key risks include Federal Reserve policy shifts and gold price volatility. Analyst sentiment appears constructive given the favorable gold market backdrop and institutional demand.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
